Show simple item record

dc.contributor.authorRitter, Thomas
dc.date.accessioned2015-11-20T12:46:33Z
dc.date.available2015-11-20T12:46:33Z
dc.date.issued2012
dc.identifier.citationSchu, S., Nosov, M., O'Flynn, L., Shaw, G., Treacy, O., Barry, F., . . . Ritter, T. (2012). Immunogenicity of allogeneic mesenchymal stem cells. Journal of Cellular and Molecular Medicine, 16(9), 2094-2103.en_IE
dc.identifier.issn1582-4934
dc.identifier.urihttp://hdl.handle.net/10379/5343
dc.descriptionJournal articleen_IE
dc.description.abstractMesenchymal stem cells (MSCs) inhibit proliferation of allogeneic T cells and express low levels of major histocompatibility complex class I (MHCI), MHCII and vascular adhesion molecule-1 (VCAM-1). We investigated whether their immunosuppressive properties and low immunophenotype protect allogeneic rat MSCs against cytotoxic lysis in vitro and result in a reduced immune response in vivo. Rat MSCs were partially protected against alloantigen-specific cytotoxic T cells in vitro. However, after treatment with IFN-? and IL-1 beta, MSCs upregulated MHCI, MHCII and VCAM-1, and cytotoxic lysis was significantly increased. In vivo, allogeneic T cells but not allogeneic MSCs induced upregulation of the activation markers CD25 and CD71 as well as downregulation of CD62L on CD4+ T cells from recipient rats. However, intravenous injection of allo-MSCs in rats led to the formation of alloantibodies with the capacity to facilitate complement-mediated lysis, although IgM levels were markedly decreased compared with animals that received T cells. The allo-MSC induced immune response was sufficient to lead to significantly reduced survival of subsequently injected allo-MSCs. Interestingly, no increased immunogenicity of IFN-? stimulated allo-MSCs was observed in vivo. Both the loss of protection against cytotoxic lysis under inflammatory conditions and the induction of complement-activating antibodies will likely impact the utility of allogeneic MSCs for therapeutic applications.en_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.relation.ispartofJournal Of Cellular And Molecular Medicineen
dc.subjectMesenchymal stem cellsen_IE
dc.subjectAllo-antibodyen_IE
dc.subjectComplementen_IE
dc.subjectImmunogenicityen_IE
dc.subjectAcute myocardial infarctionen_IE
dc.subjectProliferation in vitroen_IE
dc.subjectMarrow stromal cellsen_IE
dc.subjectVersus host diseaseen_IE
dc.subjectAcute renal failureen_IE
dc.subjectImmune responseen_IE
dc.subjectCardiac allograften_IE
dc.subjectGene therapyen_IE
dc.subjectNitric oxideen_IE
dc.subjectCalf serumen_IE
dc.titleImmunogenicity of allogeneic mesenchymal stem cellsen_IE
dc.typeArticleen_IE
dc.date.updated2015-11-19T09:51:43Z
dc.identifier.doi10.1111/j.1582-4934.2011.01509.x
dc.local.publishedsourcehttp://dx.doi.org/10.1111/j.1582-4934.2011.01509.xen_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funder|~|
dc.internal.rssid2469097
dc.local.contactThomas Ritter, School Of Medicine, Regenerative Medicine Institute, Biosciences, Dangan. 5329 Email: thomas.ritter@nuigalway.ie
dc.local.copyrightcheckedYes
dc.local.versionPUBLISHED
nui.item.downloads173


Files in this item

Attribution-NonCommercial-NoDerivs 3.0 Ireland
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. Please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.

The following license files are associated with this item:

Thumbnail

This item appears in the following Collection(s)

Show simple item record